Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14.33 | 1 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $14.33 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2017 | $14.33 | 1 | Astellas Pharma US Inc ($14.33) |
All Payment Transactions
1 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/25/2017 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: Urology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 12 | 790 | 1,129 | $261,134 | $79,831 |
| 2020 | 11 | 699 | 1,058 | $200,819 | $70,058 |
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 262 | 437 | $101,821 | $29,251 | 28.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 12 | 120 | $41,880 | $17,388 | 41.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 67 | 67 | $28,743 | $7,575 | 26.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 59 | $19,529 | $6,248 | 32.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 76 | 76 | $21,660 | $5,840 | 27.0% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Facility | 2021 | 73 | 86 | $17,864 | $5,064 | 28.3% |
| 52356 | Crushing of stone in urinary duct (ureter) with stent using an endoscope | Facility | 2021 | 11 | 12 | $12,768 | $3,682 | 28.8% |
| 55700 | Biopsy of prostate gland | Facility | 2021 | 17 | 17 | $5,678 | $1,688 | 29.7% |
| 52204 | Biopsy of the bladder using an endoscope | Facility | 2021 | 11 | 11 | $3,982 | $1,147 | 28.8% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 21 | 23 | $3,335 | $785.40 | 23.6% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 12 | 27 | $2,322 | $731.16 | 31.5% |
| 81003 | Automated urinalysis test | Office | 2021 | 172 | 194 | $1,552 | $432.00 | 27.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 225 | 375 | $69,000 | $19,888 | 28.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 13 | 96 | $33,504 | $16,509 | 49.3% |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Office | 2020 | 11 | 66 | $25,806 | $13,782 | 53.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 122 | 122 | $32,208 | $8,267 | 25.7% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Facility | 2020 | 75 | 88 | $17,864 | $4,965 | 27.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 31 | 49 | $5,439 | $1,629 | 29.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $5,642 | $1,623 | 28.8% |
| 55700 | Biopsy of prostate gland | Facility | 2020 | 13 | 13 | $4,264 | $1,229 | 28.8% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2020 | 16 | 42 | $3,234 | $1,094 | 33.8% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 13 | 13 | $2,418 | $670.27 | 27.7% |
| 81003 | Automated urinalysis test | Office | 2020 | 166 | 180 | $1,440 | $401.50 | 27.9% |
About Dr. Genji Kitagawa, DO
Dr. Genji Kitagawa, DO is a Urology healthcare provider based in Colville, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1093703191.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Genji Kitagawa, DO has received a total of $14.33 in payments from pharmaceutical and medical device companies, with $14.33 received in 2017. These payments were reported across 1 transactions from 1 company. The most common payment nature is "Food and Beverage" ($14.33).
As a Medicare-enrolled provider, Kitagawa has provided services to 1,489 Medicare beneficiaries, totaling 2,187 services with total Medicare billing of $149,889. Data is available for 2 years (2020–2021), covering 23 distinct procedure/service records.
Practice Information
- Specialty Urology
- Location Colville, WA
- Active Since 10/12/2005
- Last Updated 06/16/2021
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1093703191
Products in Payments
- Myrbetriq (Drug) $14.33
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.